Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2025 07:00 ET | Source: iBio, Inc.

iBio Announces New Investments from Board Members and Officers

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with...
January 07, 2025 07:00 ET | Source: iBio, Inc.

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the...
January 02, 2025 07:00 ET | Source: iBio, Inc.

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity...
November 25, 2024 08:00 ET | Source: iBio, Inc.

iBio Strengthens Board with Appointment of Two New Independent Directors

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David...
November 12, 2024 16:05 ET | Source: iBio, Inc.

iBio Reports Fiscal First Quarter 2025 Financial Results

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its...
October 10, 2024 08:00 ET | Source: iBio, Inc.

iBio and AstralBio Provide Update on Myostatin Program for Obesity

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for...
September 20, 2024 16:05 ET | Source: iBio, Inc.

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
September 03, 2024 07:00 ET | Source: iBio, Inc.

iBio to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin...
August 12, 2024 16:30 ET | Source: iBio, Inc.

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice...
June 03, 2024 07:00 ET | Source: iBio, Inc.

iBio Closes Sale of Manufacturing Facility in Texas

– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) --...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right